Health tech M&A is heating up

Speaking of CGM, device maker Dexcom’s presentation at this week’s all-virtual JP Morgan Healthcare Conference finally showed forward movement on its next-generation continuous glucose monitor, the G7. The company filed with the FDA in late 2021, and shared data from its submission at JPM, including results showing that the device meets the standards to feed its data into automated insulin pumps. “Our current systems have been designed to readily connect with the automated insulin delivery developments that are going to be coming out over the next several years,” said CEO Kevin Sayer. “I would even go so far as to say sharing data may be one of the most significant innovations this company has done over its history.”